Evaluation of swine protection with foot-and-mouth disease O₁/Campos and O/Primorsky/2014 vaccines against the O Mya-98 lineage virus from East Asia

Abstract

Two type O commercial vaccines, the O/Campos and O/Primorsky/2014 vaccines, were studied to evaluate the in vivo efficacy in pigs against heterologous virus challenge with the O/SKR/Jincheon/2014 virus (O/SEA/Mya-98 lineage) isolated in Korea in 2014. The in vivo challenge results indicated that both vaccines induced a high heterologous virus neutralization test (VNT) titer by a single injection and successfully protected specific pathogen-free (SPF) pigs from challenge infection. To determine the optimal vaccination age, a field trial with each vaccine was conducted with three one-shot-vaccinated groups that were injected at 8, 12, or 14 weeks of age and one two-shot-vaccinated group that was injected at 8 and 12 weeks of age in the pig farms. In these field trials, the improved serological performance at 20 and 24 weeks of age expected with vaccination at 12 or 14 weeks of age was not observed, although improved serological results were expected as the result of decreasing interference of maternally derived antibodies (MDAs), as MDAs waned with age. In addition, delayed vaccination resulted in MDA depletion at 14 weeks of age. Therefore, the optimal age for primary vaccination with two different formulated vaccines was 8 weeks old in pigs, considering that MDAs could provide a protective immunity against foot-and-mouth disease (FMD) infection. Prolonged significantly higher VNT titers of immunized pigs were demonstrated in the two-shot-vaccinated groups. In total, the effectiveness of the two vaccines was demonstrated through efficacy tests and field trials in pigs.